Related Experiment Video
Updated: Sep 12, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.3K
Prostate cancer detection with [99mTc]Tc-HYNIC-iPSMA SPECT: The Australian experience
G Currie1, P Tually2, L Groombridge3
1Charles Sturt University, Wagga Wagga, Australia.
Radiography (London, England : 1995)
|August 5, 2025
Summary
Technetium-99m-HYNIC-PSMA SPECT imaging is a safe and effective alternative for prostate cancer (PrCa) detection, especially in remote areas. This molecular imaging approach improved patient management in 41% of cases where PET/CT was not accessible.
Area of Science:
- Nuclear medicine
- Molecular imaging
- Radiopharmaceuticals
Background:
- 99mTc-HYNIC-iPSMA SPECT/CT offers a potential alternative to PET/CT for prostate cancer (PrCa) detection and staging.
- It addresses limitations in access to advanced molecular imaging, particularly for rural and socioeconomically disadvantaged populations.
- This study assessed the safety and clinical impact of 99mTc-HYNIC-iPSMA SPECT in remote Western Australian PrCa patients.
Purpose of the Study:
- To evaluate the safety and clinical utility of 99mTc-HYNIC-iPSMA SPECT imaging in a cohort of prostate cancer patients.
- To determine if this imaging modality can improve diagnostic capabilities and influence patient management in resource-limited settings.
Main Methods:
- A prospective observational study involving 27 rural Western Australian patients with confirmed prostate cancer.
- Patients received intravenous 99mTc-HYNIC-iPSMA (650-800 MBq), followed by planar whole-body, static, and SPECT/CT imaging (chest, abdomen, pelvis) 2-4 hours post-injection.
- Adverse events were monitored, and patient follow-up data were collected from medical records.
Main Results:
- No treatment-related adverse events were reported in any patient, indicating a favorable safety profile.
- Normal physiologic biodistribution was observed in 96.3% of patients, with a mean radiochemical purity of 92.5%.
- 99mTc-HYNIC-iPSMA detected at least one PSMA-positive lesion in 81.5% of patients, and findings altered management in 40.7% of cases.
Conclusions:
- 99mTc-HYNIC-iPSMA SPECT imaging is a reliable alternative imaging modality for prostate cancer, enhancing diagnostic accuracy and patient management.
- This approach significantly impacts patient care in settings where PET/CT is inaccessible, addressing geographic and socioeconomic barriers.
- The study supports 99mTc-HYNIC-iPSMA as a tool to narrow the equity gap in prostate cancer care through improved molecular imaging access.
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
235
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
235
01:29Positron Emission Tomography
5.6K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.6K